

Session Name	Session Theme	Submission No.	First Name	Last Name	Title of Abstract	Style	Month	Day	Day/Week	Min.	Session Time	Place
Plenary Session	Plenary Session	10177	Takeru	Hirao	Plasma TWEAK as a predictive biomarker of response to tremelimumab plus durvalumab in advanced hepatocellular carcinoma	Oral	April	3rd	Friday	10	16:05-16:45	Room 1 (Ito Hall, B2F)
Plenary Session	Plenary Session	10096	Long-Wang	Lin	Immune Checkpoint Inhibitors and Molecular Targeted Agents with or without TACE in Unresectable Hepatocellular Carcinoma with VP3-4 Portal Vein Tumor	Oral	April	3rd	Friday	10	16:05-16:45	Room 1 (Ito Hall, B2F)
Plenary Session	Plenary Session	10130	Norifumi	Iseda	Surgical benefit and futility in borderline resectable hepatocellular carcinoma: a multicenter study	Oral	April	3rd	Friday	10	16:05-16:45	Room 1 (Ito Hall, B2F)
Plenary Session	Plenary Session	10003	Xingru	Wang	The first application and feasibility assessment of 5G-enabled remote robot-assisted hepatobiliary and pancreatic surgery in patients with malignant tumors	Oral	April	3rd	Friday	10	16:05-16:45	Room 1 (Ito Hall, B2F)
Free Paper Session 1	Prevention and Surveillance of Hepatocellular Carcinoma Across Viral and Non-Viral Liver Diseases	10053	Passakorn	Wanchajiraboon	Implementing Community-Based Hepatitis B Screening and Hepatocellular Carcinoma Screening in Resource-Limited Settings: A Qualitative Evaluation of Thailand's EZ Liver	Oral	April	2nd	Thursday	8	09:10-10:00	Room 2 (Seminar Room, 3F)
Free Paper Session 1	Prevention and Surveillance of Hepatocellular Carcinoma Across Viral and Non-Viral Liver Diseases	10223	Mohamed	Abdel-Samiee	A Large-Center Comparison of Hepatocellular Carcinoma Characteristics in Hepatitis C Patients Treated With Direct-Acting Antivirals Versus Untreated Patients	Oral	April	2nd	Thursday	8	09:10-10:00	Room 2 (Seminar Room, 3F)
Free Paper Session 1	Prevention and Surveillance of Hepatocellular Carcinoma Across Viral and Non-Viral Liver Diseases	10107	Yuji	Ikeda	Reduced performance of alpha-fetoprotein in sustained virological response-related and non-viral early hepatocellular carcinoma: complementary value of PIVKA-Clinical Characteristics and Surveillance Impact on Non-Viral Hepatocellular Carcinoma: A 20-Year Observational Study	Oral	April	2nd	Thursday	8	09:10-10:00	Room 2 (Seminar Room, 3F)
Free Paper Session 1	Prevention and Surveillance of Hepatocellular Carcinoma Across Viral and Non-Viral Liver Diseases	10131	Katsuya	Nagaoka	Integrative clinical and molecular risk score for prevention of HBV-related HCC	Oral	April	2nd	Thursday	8	09:10-10:00	Room 2 (Seminar Room, 3F)
Free Paper Session 1	Prevention and Surveillance of Hepatocellular Carcinoma Across Viral and Non-Viral Liver Diseases	10118	Hiroyuki	Suzuki	Serum biomarker-based score to evaluate HCC risk in HCV-cured patients	Oral	April	2nd	Thursday	8	09:10-10:00	Room 2 (Seminar Room, 3F)
Free Paper Session 2	Contemporary and Emerging Issues in Hepatocellular Carcinoma	10123	Yin Min	Hwang	Hepatocellular carcinoma stage, treatment patterns, and survival outcomes in a contemporary multicentre international cohort	Oral	April	2nd	Thursday	8	10:00-10:40	Room 2 (Seminar Room, 3F)
Free Paper Session 2	Contemporary and Emerging Issues in Hepatocellular Carcinoma	10091	Juequn	Zhou	Development and validation of a deep learning model to prognosticate hepatocellular carcinoma	Oral	April	2nd	Thursday	8	10:00-10:40	Room 2 (Seminar Room, 3F)
Free Paper Session 2	Contemporary and Emerging Issues in Hepatocellular Carcinoma	10122	Amruthavarshini	Nagabhushana	Young Onset Hepatocellular carcinoma presents at advanced stage with limited treatment options.	Oral	April	2nd	Thursday	8	10:00-10:40	Room 2 (Seminar Room, 3F)
Free Paper Session 2	Contemporary and Emerging Issues in Hepatocellular Carcinoma	10136	Ankush	Kumar	Environmental Exposure to Cadmium, Lead, and Mercury as a Public Health Risk Factor for Hepatocellular Carcinoma	Oral	April	2nd	Thursday	8	10:00-10:40	Room 2 (Seminar Room, 3F)
Free Paper Session 2	Contemporary and Emerging Issues in Hepatocellular Carcinoma	10151	Takumi	Kawaguchi	Feasibility and Safety of Hepatic Rehabilitation in HCC Patients with Decompensated Cirrhosis	Oral	April	2nd	Thursday	8	10:00-10:40	Room 2 (Seminar Room, 3F)
Free Paper Session 3	Translational Insights in Biliary Tract Cancers: Tumor Biology, Biomarkers, and Clinical Implications	10011	Lei	Kong	Aging-Driven Immunosuppressive Remodeling of the Tumor Microenvironment in Gallbladder Cancer: Insights from Single-Cell Transcriptomics (oral)	Oral	April	2nd	Thursday	8	11:00-11:50	Room 2 (Seminar Room, 3F)
Free Paper Session 3	Translational Insights in Biliary Tract Cancers: Tumor Biology, Biomarkers, and Clinical Implications	10144	Xing	Yu	KLF5 Mediates a GalectinI-FBP1-RAS/ERK Cascade to Drive Proliferation and Migration in Intrahepatic Cholangiocarcinoma	Oral	April	2nd	Thursday	8	11:00-11:50	Room 2 (Seminar Room, 3F)
Free Paper Session 3	Translational Insights in Biliary Tract Cancers: Tumor Biology, Biomarkers, and Clinical Implications	10167	Yuheng	Hu	Lactylation of PPP1CA at K305 Promotes Lymph Node Metastasis in Intrahepatic Cholangiocarcinoma by Sustaining TGF- $\beta$ Signaling	Oral	April	2nd	Thursday	8	11:00-11:50	Room 2 (Seminar Room, 3F)
Free Paper Session 3	Translational Insights in Biliary Tract Cancers: Tumor Biology, Biomarkers, and Clinical Implications	10202	Asgar	Ali	Epigenetic Silencing of PTEN as a Prognostic and Translational Biomarker in Periampullary Adenocarcinoma	Oral	April	2nd	Thursday	8	11:00-11:50	Room 2 (Seminar Room, 3F)
Free Paper Session 3	Translational Insights in Biliary Tract Cancers: Tumor Biology, Biomarkers, and Clinical Implications	10184	Tsuyoshi	Takeda	Prognostic impact of adipose tissue volume in unresectable biliary tract cancer treated with gemcitabine, cisplatin, and immunotherapy	Oral	April	2nd	Thursday	8	11:00-11:50	Room 2 (Seminar Room, 3F)

Session Name	Session Theme	Submission No.	First Name	Last Name	Title of Abstract	Style	Month	Day	Day/Week	Min.	Session Time	Place
Free Paper Session 3	Translational Insights in Biliary Tract Cancers: Tumor Biology, Biomarkers, and Clinical Implications	10172	Keito	Nakagawa	Feasibility and safety of endoscopic ultrasound-guided tissue acquisition for biliary lesions	Oral	April	2nd	Thursday	8	11:00-11:50	Room 2 (Seminar Room, 3F)
Free Paper Session 4	Stress Adaptation and Tumor Evolution in Hepatocellular Carcinoma	10094	Chaiyaboot	Ariyachet	MicroRNA-199a-5p disrupts unfolded protein response-mediated stress adaptation in hepatocellular carcinoma cells	Oral	April	2nd	Thursday	8	14:50-15:30	Room 2 (Seminar Room, 3F)
Free Paper Session 4	Stress Adaptation and Tumor Evolution in Hepatocellular Carcinoma	10108	Boqiang	Liu	Dynamic Regulation of Membrane Fluidity Drives Tumor Evolution and Attenuates TNF &alpha;-Mediated Apoptosis in Hepatocellular Carcinoma	Oral	April	2nd	Thursday	8	14:50-15:30	Room 2 (Seminar Room, 3F)
Free Paper Session 4	Stress Adaptation and Tumor Evolution in Hepatocellular Carcinoma	10162	Yiming	Wang	AARS1 promotes tumor progression and immune evasion through ATF6 lactylation-driven tryptophan metabolism in hepatocellular carcinoma	Oral	April	2nd	Thursday	8	14:50-15:30	Room 2 (Seminar Room, 3F)
Free Paper Session 4	Stress Adaptation and Tumor Evolution in Hepatocellular Carcinoma	10178	Tomoya	Hamabe	Dfna5-dependent hepatocyte death promotes inflammatory TNF signaling in Kupffer cells to drive hepatocarcinogenesis	Oral	April	2nd	Thursday	8	14:50-15:30	Room 2 (Seminar Room, 3F)
Free Paper Session 5	Tumor-Immune Interactions and Translational Targets in Hepatocellular Carcinoma	10100	Liang	Shi	Natural Killer Cell Drives Liver Cancer Evolution Through Cholesterol Metabolism Reprogramming	Oral	April	2nd	Thursday	8	15:30-16:00	Room 2 (Seminar Room, 3F)
Free Paper Session 5	Tumor-Immune Interactions and Translational Targets in Hepatocellular Carcinoma	10147	Yuchan	Xue	A Fe-Curcumin-based Strategy to Reinvigorate CAR-T Cells by Reversing Exhaustion and Senescence in Liver Cancer	Oral	April	2nd	Thursday	8	15:30-16:00	Room 2 (Seminar Room, 3F)
Free Paper Session 5	Tumor-Immune Interactions and Translational Targets in Hepatocellular Carcinoma	10119	Hiroaki	Kanzaki	Reverse-engineering strategy identified DDR1 as HCC chemoprevention target post HCV cure	Oral	April	2nd	Thursday	8	15:30-16:00	Room 2 (Seminar Room, 3F)
Free Paper Session 6	Patient Selection and Risk Stratification for Systemic Therapy in Advanced Hepatocellular Carcinoma	10038	Chikako	Nagao	Clinical Characteristics of Combination Immunotherapy in Elderly Patients with Unresectable Hepatocellular Carcinoma	Oral	April	3rd	Friday	8	10:45-11:17	Room 2 (Seminar Room, 3F)
Free Paper Session 6	Patient Selection and Risk Stratification for Systemic Therapy in Advanced Hepatocellular Carcinoma	10064	Tomonao	Taira	Prognostic value of combined Child&ndash;Pugh score and modified albumin&ndash;bilirubin grade in unresectable hepatocellular carcinoma treated with atezolizumab plus	Oral	April	3rd	Friday	8	10:45-11:17	Room 2 (Seminar Room, 3F)
Free Paper Session 6	Patient Selection and Risk Stratification for Systemic Therapy in Advanced Hepatocellular Carcinoma	10106	Yumi	Otoyama	Association of Lenvatinib Pharmacokinetics with mALBI in Hepatocellular Carcinoma and Evaluation of Efficacy and Safety	Oral	April	3rd	Friday	8	10:45-11:17	Room 2 (Seminar Room, 3F)
Free Paper Session 6	Patient Selection and Risk Stratification for Systemic Therapy in Advanced Hepatocellular Carcinoma	10139	Qian	Chen	Regional Lymph Node Metastasis in Hepatocellular Carcinoma Treated with Immune-based Systemic Therapy: Prognostic Significance and Implications for Clinical	Oral	April	3rd	Friday	8	10:45-11:17	Room 2 (Seminar Room, 3F)
Free Paper Session 7	Combination and Multimodal Strategies for Advanced Hepatocellular Carcinoma with Vascular Invasion	10095	Long-Wang	Lin	Immune Checkpoint Inhibitors and Molecular Targeted Agents with or without TACE in Unresectable Hepatocellular Carcinoma with Vp1-2 Portal Vein Tumor	Oral	April	3rd	Friday	8	11:17-11:50	Room 2 (Seminar Room, 3F)
Free Paper Session 7	Combination and Multimodal Strategies for Advanced Hepatocellular Carcinoma with Vascular Invasion	10097	Long-Wang	Lin	Should Transarterial Chemoembolization Be Applied with Systemic Therapy for Hepatocellular Carcinoma with Hepatic Vein and/or Inferior Vena Cava Tumor Thrombus?:	Oral	April	3rd	Friday	8	11:17-11:50	Room 2 (Seminar Room, 3F)
Free Paper Session 7	Combination and Multimodal Strategies for Advanced Hepatocellular Carcinoma with Vascular Invasion	10160	Soe Thiha	Maung	Real-World Outcomes of Sequential Transarterial Chemoembolization followed by Atezolizumab-Bevacizumab in Patients with Advanced Hepatocellular	Oral	April	3rd	Friday	8	11:17-11:50	Room 2 (Seminar Room, 3F)
Free Paper Session 7	Combination and Multimodal Strategies for Advanced Hepatocellular Carcinoma with Vascular Invasion	10183	Joji	Tani	Efficacy of Combined Three-Dimensional Conformal Radiotherapy and Hepatic Arterial Infusion Chemotherapy for Unresectable Hepatocellular Carcinoma with Major	Oral	April	3rd	Friday	8	11:17-11:50	Room 2 (Seminar Room, 3F)
Free Paper Session 8	Surgical Decision-Making in Hepatocellular Carcinoma: Who, When, and How Far?	10111	Hayato	Abe	Prognostic impact of the oncological resectability criteria in patients undergoing liver resection for hepatocellular carcinoma	Oral	April	3rd	Friday	8	13:30-13:55	Room 2 (Seminar Room, 3F)
Free Paper Session 8	Surgical Decision-Making in Hepatocellular Carcinoma: Who, When, and How Far?	10078	Atomu	Suzuki	Surgical Outcomes and Treatment Strategies for Solitary Giant Hepatocellular Carcinoma	Oral	April	3rd	Friday	8	13:30-13:55	Room 2 (Seminar Room, 3F)
Free Paper Session 8	Surgical Decision-Making in Hepatocellular Carcinoma: Who, When, and How Far?	10146	Ting	Luo	Association between prophylactic antibiotics and post-ablation infections in hepatocellular carcinoma patients: a retrospective multicenter cohort study	Oral	April	3rd	Friday	8	13:30-13:55	Room 2 (Seminar Room, 3F)
Free Paper Session 9	Locoregional Approaches in Hepatocellular Carcinoma: From Treatment Response to Hemodynamic Management	10076	Chitchai	Rattananukrom	PIVKA-II Monitoring to Predict Response to The First Transarterial Chemoembolization (TACE) in Intermediate-Stage Hepatocellular Carcinoma	Oral	April	3rd	Friday	8	13:55-14:15	Room 2 (Seminar Room, 3F)

Session Name	Session Theme	Submission No.	First Name	Last Name	Title of Abstract	Style	Month	Day	Day/Week	Min.	Session Time	Place
Free Paper Session 9	Locoregional Approaches in Hepatocellular Carcinoma: From Treatment Response to Hemodynamic Management	10158	Atteyat	Semeya	Role of Transjugular Intrahepatic Portosystemic Shunt (TIPS) in Refractory Gastrointestinal Bleeding in Hepatocellular Carcinoma Patients with Portal Vein	Oral	April	3rd	Friday	8	13:55-14:15	Room 2 (Seminar Room, 3F)
Free Paper Session 10	Imaging and Radiation in Hepatocellular Carcinoma: From Diagnosis to Therapeutic Synergy	10029	Masaya	Sato	Development of Novel Deep Multimodal Representation Learning-based Model for the Differentiation of Liver Tumors on B-Mode Ultrasound Images	Oral	April	3rd	Friday	8	14:15-14:45	Room 2 (Seminar Room, 3F)
Free Paper Session 10	Imaging and Radiation in Hepatocellular Carcinoma: From Diagnosis to Therapeutic Synergy	10204	Aldisa	Puspitasari	Dissociation Between Multiphasic CT-Defined Tumor Burden and Endoscopic Portal Hypertension Severity in Cirrhotic and Non-Cirrhotic Hepatocellular Carcinoma	Oral	April	3rd	Friday	8	14:15-14:45	Room 2 (Seminar Room, 3F)
Free Paper Session 10	Imaging and Radiation in Hepatocellular Carcinoma: From Diagnosis to Therapeutic Synergy	10210	Phool	Chand	Stereotactic Body Radiotherapy Enhances the Efficacy of Nivolumab in Advanced Hepatocellular Carcinoma: A Comparative Cohort Analysis.	Oral	April	3rd	Friday	8	14:15-14:45	Room 2 (Seminar Room, 3F)
Late Breaker Session 1	Immunobiology and Translational Insights in Liver Cancer	10248	Wenjing	Yuan	HLA-DR<sup>+</sup> tumor cells mimic antigen-presenting cells to mediate immunosuppression in HBV-related hepatocellular carcinoma	Oral	April	3rd	Thursday	8	13:30-14:02	Room 2 (Seminar Room, 3F)
Late Breaker Session 1	Immunobiology and Translational Insights in Liver Cancer	10236	Jinhui	Wei	High ammonia promotes EHHADH-dependent pyrimidine degradation to induce inflammatory cell death in HCC	Oral	April	3rd	Thursday	8	13:30-14:02	Room 2 (Seminar Room, 3F)
Late Breaker Session 1	Immunobiology and Translational Insights in Liver Cancer	10239	Ryo	Morisue	Sarcomatoid transformation is associated with immunosuppressive remodeling in hepatocellular carcinoma	Oral	April	3rd	Thursday	8	13:30-14:02	Room 2 (Seminar Room, 3F)
Late Breaker Session 1	Immunobiology and Translational Insights in Liver Cancer	10254	Hiroshi	Ohyama	Bile-based liquid biopsy for diagnosis and therapeutic stratification of biliary strictures	Oral	April	3rd	Thursday	8	13:30-14:02	Room 2 (Seminar Room, 3F)
Late Breaker Session 2	Precision Decision-Making and Treatment Strategies in Hepatobiliary Cancer	10246	Amith	Vishwanath	Large Language Models Underperform Multidisciplinary Teams for Hepatocellular Carcinoma Treatment Decisions Despite Escalating Prompting Strategies: A Prospective	Oral	April	3rd	Thursday	8	14:02-14:35	Room 2 (Seminar Room, 3F)
Late Breaker Session 2	Precision Decision-Making and Treatment Strategies in Hepatobiliary Cancer	10272	Jun-Hao	Mei	Causal Machine Learning-Guided Personalized Immunochemotherapy Strategies in Intrahepatic Cholangiocarcinoma	Oral	April	3rd	Thursday	8	14:02-14:35	Room 2 (Seminar Room, 3F)
Late Breaker Session 2	Precision Decision-Making and Treatment Strategies in Hepatobiliary Cancer	10232	Jianhua	Rao	NEO-ERA-01: A phase II study of neoadjuvant HAIC (GEMOX) plus adefrelimab and lenvatinib in high-risk resectable intrahepatic cholangiocarcinoma	Oral	April	3rd	Thursday	8	14:02-14:35	Room 2 (Seminar Room, 3F)
Late Breaker Session 2	Precision Decision-Making and Treatment Strategies in Hepatobiliary Cancer	10250	Shuntaro	Obi	Stage-dependent liver stiffness resolution after HCV SVR: a longitudinal 8-year follow-up study	Oral	April	3rd	Thursday	8	14:02-14:35	Room 2 (Seminar Room, 3F)
Video Session	Mastering Complex Hepato-Biliary Procedures: Pitfalls, Navigation, and Advanced Minimally Invasive Techniques	10073	Gakushi	Kitamura	Pitfalls in Posterior Sectionectomy and S7 Segmentectomy Focusing on the Running Pattern of the Right Posterior Inferior Portal Branch (P6a) and Portal Vein Branching	Oral	April	3rd	Friday	12	09:00-10:30	Room 2 (Seminar Room, 3F)
Video Session	Mastering Complex Hepato-Biliary Procedures: Pitfalls, Navigation, and Advanced Minimally Invasive Techniques	10074	Yusuke	Yamamoto	Surgical Strategy for Laparoscopic Right Intersectional Plane Resection in Right Anterior/Posterior Sectionectomy and S7/S8 Segmentectomy, Based on the Courses of P6a and	Oral	April	3rd	Friday	12	09:00-10:30	Room 2 (Seminar Room, 3F)
Video Session	Mastering Complex Hepato-Biliary Procedures: Pitfalls, Navigation, and Advanced Minimally Invasive Techniques	10004	Xingru	Wang	Infrared laser-guided laparoscopic portal vein drainage area Anatomic Liver Resection using ICG positive staining	Oral	April	3rd	Friday	12	09:00-10:30	Room 2 (Seminar Room, 3F)
Video Session	Mastering Complex Hepato-Biliary Procedures: Pitfalls, Navigation, and Advanced Minimally Invasive Techniques	10077	Rie	Shibata	Optimizing Specimen Extraction in Laparoscopic Resection of Giant Liver Tumors Using a Pfannenstiel Incision	Oral	April	3rd	Friday	12	09:00-10:30	Room 2 (Seminar Room, 3F)
Video Session	Mastering Complex Hepato-Biliary Procedures: Pitfalls, Navigation, and Advanced Minimally Invasive Techniques	10143	Taisuke	Imamura	Advanced Minimally Invasive Hepatectomy Through Standardized Hepatic Vein Control- Translating Laparoscopic Strategies to Robotic Surgery -	Oral	April	3rd	Friday	12	09:00-10:30	Room 2 (Seminar Room, 3F)
Video Session	Mastering Complex Hepato-Biliary Procedures: Pitfalls, Navigation, and Advanced Minimally Invasive Techniques	10069	Mei	Nakamura	Initial experience with robot-assisted liver resection using the da Vinci SP system	Oral	April	3rd	Friday	12	09:00-10:30	Room 2 (Seminar Room, 3F)
Video Session	Mastering Complex Hepato-Biliary Procedures: Pitfalls, Navigation, and Advanced Minimally Invasive Techniques	10090	Hiroki	Yamana	EUS-Guided Portal Vein Sampling as a Novel Liquid Biopsy Approach for Pancreatic cancer	Oral	April	3rd	Friday	12	09:00-10:30	Room 2 (Seminar Room, 3F)
Young Investigator Award Session I	Rising Stars in Liver Oncology: Mechanisms, Metabolism, and the Tumor Microenvironment	10013	Vanilla Xin	Zhang	Repurposing Resmetirom suppresses MASH-associated hepatocellular carcinoma, with mechanistic implications of MDK/LRP1-mediated metabolic reprogramming and	Oral	April	3rd	Friday	8	15:00-15:32	Room 2 (Seminar Room, 3F)

Session Name	Session Theme	Submission No.	First Name	Last Name	Title of Abstract	Style	Month	Day	Day/Week	Min.	Session Time	Place
Young Investigator Award Session 1	Rising Stars in Liver Oncology: Mechanisms, Metabolism, and the Tumor Microenvironment	10017	Firdian	Makrufardi	Transitional Hepatocytes and Immunosuppressive Macrophages Drive NASH-Associated Liver Cancer Revealed by Single-Cell Transcriptomics	Oral	April	3rd	Friday	8	15:00-15:32	Room 2 (Seminar Room, 3F)
Young Investigator Award Session 1	Rising Stars in Liver Oncology: Mechanisms, Metabolism, and the Tumor Microenvironment	10047	Kenji	Nose	Gemcitabine modulates the tumor immune microenvironment to enhance response to immune-checkpoint inhibitors in biliary tract cancer	Oral	April	3rd	Friday	8	15:00-15:32	Room 2 (Seminar Room, 3F)
Young Investigator Award Session 1	Rising Stars in Liver Oncology: Mechanisms, Metabolism, and the Tumor Microenvironment	10065	Masaki	Omori	Strategic integration of locoregional interventions to optimize survival outcomes following first-line ICI combinations in advanced hepatocellular carcinoma	Oral	April	3rd	Friday	8	15:00-15:32	Room 2 (Seminar Room, 3F)
Young Investigator Award Session 2	Rising Stars in Liver Oncology: Clinical Prediction, Risk Stratification, and Real-World Challenges	10020	Takashi	Kitagataya	Impact of Antihypertensive Drug Selection on Proteinuria Risk During Atezolizumab Plus Bevacizumab Therapy for Hepatocellular Carcinoma	Oral	April	3rd	Friday	8	15:32-16:05	Room 2 (Seminar Room, 3F)
Young Investigator Award Session 2	Rising Stars in Liver Oncology: Clinical Prediction, Risk Stratification, and Real-World Challenges	10060	Satoshi	Narahara	Pretreatment Serum Heparin-Binding Protein as a Predictive Biomarker for Atezolizumab Plus Bevacizumab Therapy in Advanced Hepatocellular Carcinoma.	Oral	April	3rd	Friday	8	15:32-16:05	Room 2 (Seminar Room, 3F)
Young Investigator Award Session 2	Rising Stars in Liver Oncology: Clinical Prediction, Risk Stratification, and Real-World Challenges	10041	Tomoaki	Hayakawa	Novel Risk Score Incorporating Type-IV Collagen, Albumin, and Prothrombin Time (CAP score) to Predict 180-Day Surgery-Related Mortality After Liver Resection	Oral	April	3rd	Friday	8	15:32-16:05	Room 2 (Seminar Room, 3F)
Young Investigator Award Session 2	Rising Stars in Liver Oncology: Clinical Prediction, Risk Stratification, and Real-World Challenges	10070	Takuma	Kaneko	Unexpected Rapid Progression of Hepatocellular Carcinoma After Radiofrequency Ablation	Oral	April	3rd	Friday	8	15:32-16:05	Room 2 (Seminar Room, 3F)